182 related articles for article (PubMed ID: 36060948)
1. Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children.
Erazmus M; Rumińska M; Witkowska-Sędek E; Kucharska AM; Stelmaszczyk-Emmel A; Majcher A; Pyrżak B
Front Endocrinol (Lausanne); 2022; 13():963467. PubMed ID: 36060948
[TBL] [Abstract][Full Text] [Related]
2. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
[TBL] [Abstract][Full Text] [Related]
3. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.
Ashley DT; O'Sullivan EP; Davenport C; Devlin N; Crowley RK; McCaffrey N; Moyna NM; Smith D; O'Gorman DJ
Metabolism; 2011 Jul; 60(7):994-1000. PubMed ID: 21087777
[TBL] [Abstract][Full Text] [Related]
4. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women.
Ostrowska Z; Kos-Kudła B; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K
Postepy Hig Med Dosw (Online); 2011 Oct; 65():658-67. PubMed ID: 22100799
[TBL] [Abstract][Full Text] [Related]
5. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
[TBL] [Abstract][Full Text] [Related]
6. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
Dovio A; Data V; Carignola R; Calzolari G; Vitetta R; Ventura M; Saba L; Severino A; Angeli A
J Rheumatol; 2008 Nov; 35(11):2206-13. PubMed ID: 18843778
[TBL] [Abstract][Full Text] [Related]
7. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.
Wasilewska A; Rybi-Szuminska AA; Zoch-Zwierz W
J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1099-104. PubMed ID: 20333868
[TBL] [Abstract][Full Text] [Related]
8. Carotid intima media thickness and associations with serum osteoprotegerin and s-RANKL in children and adolescents with type 1 diabetes mellitus with increased risk for endothelial dysfunction.
Karavanaki K; Tsouvalas E; Vakaki M; Soldatou A; Tsentidis C; Kaparos G; Augoulea A; Alexandrou A; Lambrinoudaki Ι
J Pediatr Endocrinol Metab; 2018 Nov; 31(11):1169-1177. PubMed ID: 30352039
[TBL] [Abstract][Full Text] [Related]
9. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
[TBL] [Abstract][Full Text] [Related]
10. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
[TBL] [Abstract][Full Text] [Related]
11. Association of OPG-RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths.
Zampetti S; Lucantoni F; Pacifico L; Campagna G; Versacci P; Pierimarchi P; Buzzetti R
J Endocrinol Invest; 2019 Apr; 42(4):427-434. PubMed ID: 30132289
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of zinc supplementation against cadmium-induced oxidative stress and the RANK/RANKL/OPG system imbalance in the bone tissue of rats.
Brzóska MM; Rogalska J
Toxicol Appl Pharmacol; 2013 Oct; 272(1):208-20. PubMed ID: 23726800
[TBL] [Abstract][Full Text] [Related]
13. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
Carmona-Fernandes D; Santos MJ; Perpétuo IP; Fonseca JE; Canhão H
Arthritis Res Ther; 2011; 13(5):R175. PubMed ID: 22027240
[TBL] [Abstract][Full Text] [Related]
14. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort.
Tietze H; Pott V; Kanzelmeyer N; Memaran N; Baumann U; Mindermann C; Suhlrie A; Drube J; Melk A; Das AM; Schnabel D; Haffner D; Leifheit-Nestler M
Osteoporos Int; 2024 Mar; 35(3):533-542. PubMed ID: 37940696
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
16. OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.
LaCroix AZ; Jackson RD; Aragaki A; Kooperberg C; Cauley JA; Chen Z; Leboff MS; Duggan D; Wactawski-Wende J
Bone; 2013 Oct; 56(2):474-81. PubMed ID: 23735608
[TBL] [Abstract][Full Text] [Related]
17. Relationship between insulin resistance, hs-CRP, and body fat and serum osteoprotegerin/RANKL in prediabetic patients.
Bilgir O; Yavuz M; Bilgir F; Akan OY; Bayindir AG; Calan M; Bozkaya G; Yuksel A
Minerva Endocrinol; 2018 Mar; 43(1):19-26. PubMed ID: 28146138
[TBL] [Abstract][Full Text] [Related]
18. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
[TBL] [Abstract][Full Text] [Related]
19. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
Pepene CE; Ilie IR; Marian I; Duncea I
Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.
Raaz-Schrauder D; Schrauder MG; Stumpf C; Lewczuk P; Kilian T; Dietel B; Garlichs CD; Schlundt C; Achenbach S; Klinghammer L
Heart Vessels; 2017 Nov; 32(11):1304-1313. PubMed ID: 28567553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
